Regulators expand review time for Novartis’ MS drug
Regulatory action is now expected in September 2020
Read More
Tag: B-cell therapy
- Samsung Bioepis signs partnership with Sandoz for next‑generation biosimilars
- Atrogi begins dosing first subjects in human trial of ATR-258
- R1 Therapeutics launches with $77.5m to advance hyperphosphatemia treatment
- Taiwan Bio partners with Terumo to advance automated Treg manufacturing
- Elevara begins phase 2b trial of ELV001 in rheumatoid arthritis
